Confirm delete?

Bertin Pharma
logo

Search

Contact Us
Click on the map to find a distributor

Internal page

By Drug Discovery & Translational Research, Bertin Pharma objective is to evidence the efficacy of new molecules, drugs (i.e. chemical substances) or biologics and vaccines and to determine their mode of action (Primary pharmacodynamic -PD), concomitantly to predict their eventual adverse effects (toxicity & off-target interactions).

Efficacy/Cytotoxicity



For this, Bertin Pharma uses these different cell models in order to screen your drug products and to highlight in cellulo their efficacy and their absence of cytotoxicity. One reference molecule is tested in parallel of your drug products and 50, 70 & 90% effective and cytotoxic doses as well as selectivity index are systematically calculated. Then, effects of lead compounds in primary cultures of relevant cells, their mode of action, their interactions with drugs routinely used in clinic are evaluated.

Cell & Animal models

These initial results then lead naturally to pharmacokinetics (PK), early ADME and a proof of concept in animal models (mouse, rat, rabbit &Not Humanized primate - NHP) mimicking at best pathologies in Humans. Indeed, many of our cell &/or animal models are designed to be as close as possible to the pathophysiology of target diseases). All these following phases can be supported by Bertin Pharma and this is the same for regulatory Tox studies*.

maximus lacus! Etiam faucibus viverra tortor, at dapibus orci tincidunt vel. Praesent vehicula eros ac eleifend tempus. Suspendisse porttitor, mi in ullamcorper scelerisque, ipsum augue congue enim, at vehicula urna turpis ut mauris.

maximus lacus! Etiam faucibus viverra tortor, at dapibus orci tincidunt vel. Praesent vehicula eros ac eleifend tempus. Suspendisse porttitor, mi in ullamcorper scelerisque, ipsum augue congue enim, at vehicula urna turpis ut mauris.

Large scope of expertise

These initial results then lead naturally to pharmacokinetics (PK), early ADME and a proof of concept in animal models (mouse, rat, rabbit &Not Humanized primate - NHP) mimicking at best pathologies in Humans. Indeed, many of our cell &/or animal models are designed to be as close as possible to the pathophysiology of target diseases). All these following phases can be supported by Bertin Pharma and this is the same for regulatory

Top